Lantern Pharma (NASDAQ:LTRN – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports.
Lantern Pharma Stock Down 6.8 %
LTRN opened at $5.38 on Thursday. Lantern Pharma has a 52 week low of $2.38 and a 52 week high of $11.99. The business has a fifty day simple moving average of $6.71 and a 200-day simple moving average of $4.80. The firm has a market cap of $57.78 million, a P/E ratio of -3.64 and a beta of 1.41.
Lantern Pharma (NASDAQ:LTRN – Get Free Report) last released its quarterly earnings results on Monday, March 18th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. Sell-side analysts expect that Lantern Pharma will post -2.02 earnings per share for the current year.
Insider Activity
Institutional Trading of Lantern Pharma
An institutional investor recently bought a new position in Lantern Pharma stock. Meridian Wealth Management LLC purchased a new stake in Lantern Pharma Inc. (NASDAQ:LTRN – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,660 shares of the company’s stock, valued at approximately $57,000. Meridian Wealth Management LLC owned approximately 0.15% of Lantern Pharma at the end of the most recent reporting period. 28.62% of the stock is owned by institutional investors.
Lantern Pharma Company Profile
Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.
Recommended Stories
- Five stocks we like better than Lantern Pharma
- The 3 Best Blue-Chip Stocks to Buy Now
- Nucor Stock Earnings Riding the Steel Industry Wave
- Basic Materials Stocks Investing
- Simpson Manufacturing: Buy This Future Dividend King While Down
- What is the NASDAQ Stock Exchange?
- Is Boeing Stock About to Soar Higher?
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.